PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma

References

• Chen W , Zheng R , Baade PD , et al. Cancer statistics in China, 2015. CA Cancer J Clin . 2016;66(2):115–132. doi:10.3322/caac.21338 26808342
   PubMed Web of Science ®Google Scholar
• Wang L , Ma Q , Yao R , Liu J . Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. Int Immunopharmacol . 2020;79:106088. doi:10.1016/j.intimp.2019.106088 31896512
   PubMed Web of Science ®Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–546. doi:10.1038/nrc3775
   Google Scholar
• Gandara DR , Hammerman PS , Sos ML , Lara PN Jr. , Hirsch FR . Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res . 2015;21(10):2236–2243. doi:10.1158/1078-0432.Ccr-14-3039 25979930
   PubMed Web of Science ®Google Scholar
• Langer CJ , Redman MW , Wade JL 3rd , et al. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for previously treated PI3K-positive patients with stage IV squamous cell lung cancer (lung-MAP sub-study). J Thorac Oncol . 2019;14(10):1839–1846. doi:10.1016/j.jtho.2019.05.029 31158500
   PubMed Web of Science ®Google Scholar
• Goss GD , Felip E , Cobo M , et al. Association of ERBB mutations with clinical outcomes of afatinib- or erlotinib-treated patients with lung squamous cell carcinoma: secondary analysis of the LUX-lung 8 Randomized Clinical Trial. JAMA Oncol . 2018;4(9):1189–1197. doi:10.1001/jamaoncol.2018.0775 29902295
   PubMed Web of Science ®Google Scholar
• Ma G , Deng Y , Jiang H , Li W , Wu Q , Zhou Q . The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: an updated meta-analysis. Clini Chim Acta . 2018;482:101–107. doi:10.1016/j.cca.2018.03.038
   PubMed Web of Science ®Google Scholar
• Lee KS , Kim BH , Oh HK , et al. Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: implications for prognosis. Cancer Sci . 2018;109(9):2957–2969. doi:10.1111/cas.13716 29949671
   PubMed Web of Science ®Google Scholar
• Takada K , Okamoto T , Toyokawa G , et al. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Lung Cancer . 2017;104:7–15. doi:10.1016/j.lungcan.2016.12.006 28213003
   PubMed Web of Science ®Google Scholar
• Sun JM , Zhou W , Choi YL , et al. Prognostic significance of PD-L1 in patients with non-small cell lung cancer: a large cohort study of surgically resected cases. J Thorac Oncol . 2016;11(7):1003–1011. doi:10.1016/j.jtho.2016.04.007 27103510
   PubMed Web of Science ®Google Scholar
• Ceeraz S , Nowak EC , Noelle RJ . B7 family checkpoint regulators in immune regulation and disease. Trends Immunol . 2013;34(11):556–563. doi:10.1016/j.it.2013.07.003 23954143
   PubMed Web of Science ®Google Scholar
• Roemer MG , Advani RH , Ligon AH , et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol . 2016;34(23):2690–2697. doi:10.1200/JCO.2016.66.4482 27069084
   PubMed Web of Science ®Google Scholar
• Ma LJ , Feng FL , Dong LQ , et al. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics . 2018;8(20):5690–5702. doi:10.7150/thno.28742 30555574
   PubMed Web of Science ®Google Scholar
• Liu Y , Wang JF , Li XW , Bu P , Bai W , Li LM . Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues. Zhonghua Bing Li Xue Za Zhi . 2018;47(8):597–602. Chinese. doi:10.3760/cma.j.issn.0529-5807.2018.08.006 30107664
   PubMedGoogle Scholar
• Inoue Y , Yoshimura K , Nishimoto K , et al. Evaluation of programmed death ligand 1 (PD-L1) gene amplification and response to nivolumab monotherapy in non-small cell lung cancer. JAMA Netw Open . 2020;3(9):e2011818. doi:10.1001/jamanetworkopen.2020.11818 32955570
   PubMed Web of Science ®Google Scholar
• Goodman AM , Piccioni D , Kato S , et al. Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol . 2018;4(9):1237–1244. doi:10.1001/jamaoncol.2018.1701 29902298
   PubMed Web of Science ®Google Scholar
• Pedoeem A , Azoulay-Alfaguter I , Strazza M , Silverman GJ , Mor A . Programmed death-1 pathway in cancer and autoimmunity. Clin immunol . 2014;153(1):145–152. doi:10.1016/j.clim.2014.04.010 24780173
   PubMed Web of Science ®Google Scholar
• Hui E , Cheung J , Zhu J , et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science . 2017;355(6332):1428–1433. doi:10.1126/science.aaf1292 28280247
   PubMed Web of Science ®Google Scholar
• Ning Y , Shen K , Wu Q , et al. Tumor exosomes block dendritic cells maturation to decrease the T cell immune response. Immunol Lett . 2018;199:36–43. doi:10.1016/j.imlet.2018.05.002 29800589
   PubMed Web of Science ®Google Scholar
• Poggio M , Hu T , Pai CC , et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell . 2019;177(2):414–27.e13. doi:10.1016/j.cell.2019.02.016 30951669
   PubMed Web of Science ®Google Scholar
• Lin G , Fan X , Zhu W , et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget . 2017;8(48):83986–83994. doi:10.18632/oncotarget.20233 29137398
   PubMedGoogle Scholar
• Chen YB , Mu CY , Huang JA . Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori . 2012;98(6):751–755. doi:10.1700/1217.13499 23389362
   PubMed Web of Science ®Google Scholar
• Cooper WA , Tran T , Vilain RE , et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer . 2015;89(2):181–188. doi:10.1016/j.lungcan.2015.05.007 26024796
   PubMed Web of Science ®Google Scholar
• Yang CY , Lin MW , Chang YL , Wu CT , Yang PC . Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer . 2016;57:91–103. doi:10.1016/j.ejca.2015.12.033 26901614
   PubMed Web of Science ®Google Scholar
• Yang CY , Lin MW , Chang YL , Wu CT , Yang PC . Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer . 2014;50(7):1361–1369. doi:10.1016/j.ejca.2014.01.018 24548766
   PubMed Web of Science ®Google Scholar
• Velcheti V , Schalper KA , Carvajal DE , et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest . 2014;94(1):107–116. doi:10.1038/labinvest.2013.130 24217091
   PubMed Web of Science ®Google Scholar
• Ameratunga M , Asadi K , Lin X , et al. PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected nSCLC. PLoS One . 2016;11(4):e0153954. doi:10.1371/journal.pone.0153954 27104612
   PubMed Web of Science ®Google Scholar
• Zhang Y , Wang L , Li Y , et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther . 2014;7:567–573. doi:10.2147/ott.S59959 24748806
   PubMed Web of Science ®Google Scholar
• Becker A , Thakur BK , Weiss JM , Kim HS , Peinado H , Lyden D . Extracellular Vesicles in Cancer: cell-to-cell mediators of metastasis. Cancer Cell . 2016;30(6):836–848. doi:10.1016/j.ccell.2016.10.009 27960084
   PubMed Web of Science ®Google Scholar
• Schmidt LH , Kümmel A , Görlich D , et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One . 2015;10(8):e0136023. doi:10.1371/journal.pone.0136023 26313362
   PubMed Web of Science ®Google Scholar
• Tokito T , Azuma K , Kawahara A , et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer . 2016;55:7–14. doi:10.1016/j.ejca.2015.11.020 26771872
   PubMed Web of Science ®Google Scholar
• Okita R , Maeda A , Shimizu K , Nojima Y , Saisho S , Nakata M . PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol Immun . 2017;66(7):865–876. doi:10.1007/s00262-017-1986-y
   PubMed Web of Science ®Google Scholar
• Wang K , Wang J , Wei F , Zhao N , Yang F , Ren X . Expression of TLR4 in non-small cell lung cancer is associated with PD-L1 and poor prognosis in patients receiving pulmonectomy. Front Immunol . 2017;8:456. doi:10.3389/fimmu.2017.00456 28484456
   PubMed Web of Science ®Google Scholar
• He Y , Rozeboom L , Rivard CJ , et al. PD-1, PD-L1 protein expression in non-small cell lung cancer and their relationship with tumor-infiltrating lymphocytes. Med Sci Monitor . 2017;23:1208–1216. doi:10.12659/msm.899909
   PubMed Web of Science ®Google Scholar
• Okuma Y , Hishima T , Kashima J , Homma S . High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer. Cancer Immunol Immun . 2018;67(3):495–505. doi:10.1007/s00262-017-2103-y
   PubMed Web of Science ®Google Scholar
• Inoue Y , Yoshimura K , Mori K , et al. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. Oncotarget . 2016;7(22):32113–32128. doi:10.18632/oncotarget.8528 27050074
   PubMed Web of Science ®Google Scholar
• Ikeda S , Okamoto T , Okano S , et al. PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer. J Thorac Oncol . 2016;11(1):62–71. doi:10.1016/j.jtho.2015.09.010 26762740
   PubMed Web of Science ®Google Scholar